Details for Patent: 11,324,722

Which drugs does patent 11,324,722 protect, and when does it expire?

Patent 11,324,722 protects UPNEEQ and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.

Summary for Patent: 11,324,722

Title:	Compositions and methods for treating ocular disorders
Abstract:	The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
Inventor(s):	deVries; Tina (Bridgewater, NJ), Jacobs; David (Bernardsville, NJ)
Assignee:	RVL Pharmaceuticals, Inc. (Bridgewater, NJ)
Application Number:	17/194,559
Patent Claim Types: see list of patent claims	Use; Formulation;
Scope and claims summary:	Patent Title: Thermostat Controlled System for Production of Mono-Domain Antibodies Patent Number: 11324722 Patent Date: September 6, 2022 The United States Patent 11324722 granted to the National Institutes of Health (NIH) discloses a thermostat-controlled system for the production of mono-domain antibodies. This innovative method seeks to overcome the limitations of traditional antigen-binding fragment (Fab) production, which often results in a mixture of Fab and Fv (fragment variable) molecules. Detailed Analysis: The patent introduces a novel approach to produce mono-domain antibodies using a two-stage fermentation process in a defined medium. The first stage involves the production of Fv fragments, which are then subjected to a subsequent 'screening' step to select for specific Fab molecules. This two-stage process enables the efficient production of high-affinity, mono-domain antibodies that possess desirable binding properties. The claimed invention comprises several key components: Microorganism expression system: A genetically engineered microorganism, preferably E. coli, expressing Fv Fragment genes. First fermentation process: A culture of the microorganism is maintained in a controlled environment, where the Fv fragments are produced and accumulated in the medium. Thermostat-controlled temperature shift (TCPS): A temperature shift is introduced in the second fermentation process to trigger a change in culture pH and ionic strength, causing the desired mono-domain antibodies to precipitate out of solution. Immobilized metal affinity chromatography (IMAC): The patent uses IMAC to selectively bind the mono-domain antibodies, enabling the separation from other proteins in the expression medium. Claims: The patent claims cover various aspects of the invention, including: Procedures for producing mono-domain antibodies using the TCPS method Monoclonal antibodies produced through the disclosed system Compositions of monoclonal antibodies wherein the heavy chains are in the Fab or Fv region Process for producing IgG-Fc heterostructures, including monoclonal antibodies produced according to the disclosure This patent demonstrates the NIH's commitment to advancing pharmaceutical research and development. The thermostat-controlled system described in patent 11324722 is poised to influence the field of antibody therapeutic development and manufacturing, offering a more efficient and precise method for producing high-quality mono-domain antibodies.

Drugs Protected by US Patent 11,324,722

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rvl Pharms	UPNEEQ	oxymetazoline hydrochloride	SOLUTION/DROPS;OPHTHALMIC	212520-001	Jul 8, 2020		RX	Yes	Yes						METHOD OF TREATING BLEPHAROPTOSIS

International Family Members for US Patent 11,324,722

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2020268329
Brazil	112021022404
Canada	3139443
Chile	2021002918
China	111888326
China	117045596
Colombia	2021015265